echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Nuocheng Jianhua's FGFR inhibitor gunagratinib was approved as an orphan drug by the U.S. FDA

    Nuocheng Jianhua's FGFR inhibitor gunagratinib was approved as an orphan drug by the U.S. FDA

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nuocheng Jianhua announced today that the company's self-developed highly selective pan-FGFR (fibroblast growth factor receptor) inhibitor gunagratinib (ICP-192) has been granted Orphan Drug designation by the U.
    S.
    Food and Drug Administration (FDA).
    Designation, ODD), used to treat cholangiocarcinoma
    .

    ICP-192 is a class 1 innovative drug with global independent intellectual property rights under Nuocheng Jianhua.
    It is a small molecule pan-FGFR inhibitor that can be used to treat a variety of solid tumors and is highly selective.
    It is currently conducting multiple clinical trials in China and the United States.
    Research
    .

    The latest clinical data of gunagratinib announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting shows that as of February 2021, a total of 30 patients have received gunagratinib treatment
    .


    The safety and tolerance are good, and the maximum tolerated dose (MTD) has not been reached


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.